Business
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945
About this update from Indivior Pharmaceuticals, Inc.
[{"type":"text","content":"Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected in the Range of $430 million to $450 millionAdjusted EBITDA Expected in the Range of $535 million to $575 million RICHMOND, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) (“Indivior PLC” or the “Company”) today announced its full-year 2026 financial guidance. “2025 was a transition year for Indivior in which we established the Indivior Action Agenda and completed Phase I – Generate Momentum – by growing U.S. SUBLOCADE net revenue, simplifying the organization and transforming our operating model,” said Joe Ciaffoni, Chief Executive Officer. “We enter 2026 well positioned to execute on Phase II – Accelerate – which includes accelerating U.S. SUBLOCADE dispense unit growth and SUBLOCADE net revenue throughout 2026 and immediately accelerating adjusted EBITDA and cash flow at a faster rate.” “Our 2026 financial guidance reflects SUBLOCADE net revenue growth, driven by an acceleration in dispense units, and significant margin expansion from our simplified operating model,” said Ryan Preblick, Chief Financial Officer. “In 2026, we expect to grow SUBLOCADE net revenue by 11% at the midpoint of our guidance range while growing adjusted EBITDA by 35% and adjusted EBITDA margin by 14 percentage points.” Recent Business Highlights: Completed Phase I of the Indivior Action Agenda — Generate Momentum – which included growing U.S. SUBLOCADE net revenue, simplifying the organization and transforming the Company’s operating model resulting in expected annual non-GAAP operating expense savings of at least $150 million.Entered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026, which is focused on accelerating U.S. SUBLOCADE dispense unit growth and net revenue throughout 2026 and immediately accelerating adjusted EBITDA and cash flow at a faster rate.Gained inclusion in the S&P SmallCap 600® index effective December 22, 2025.Received shareholder approval of the Company’s proposal to change its domicile from the U.K. to the U.S. and establish a new U.S. parent company, Indivior Pharmaceuticals, Inc. The change in domicile is expected to take effect on January 26, 2026.Concluded the legacy U.S. Department of ...